INN – Imiglucerase

Imiglucerase replaces the deficiency of this enzyme, ceases to initial pathophysiological changes and prevents secondary pathological manifestations of disease.

Glurazyme® treatment reduces size of spleen and liver, normalizes blood platelet counts, mineral bone density, reduces bone-marrow infiltration, weakening pain in the bones.

Therapeutic indications:

Glurazyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.

The non-neurological manifestations of Gaucher disease include one or more of the following conditions:

  • anaemia
  • thrombocytopenia
  • bone disease
  • hepatomegaly or splenomegaly

«GENERIUM» is the only one company in Russia that carried out the development and production of Imiglucerase biosimilar.